key: cord-0955852-kqmujatn
authors: Paul, Mical; Kalil, Andre C.
title: Intended category: Invited editorial repurposed drugs for COVID-19: threshold and proof requirements for trials
date: 2021-09-08
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.08.024
sha: b29ccb14d3348a691b6f367d0303371d4298b3e3
doc_id: 955852
cord_uid: kqmujatn

nan

In the current issue of the journal Ader et al. report results for hydroxychloroquine and lopinavir/ritonavir with or without interferon-β-1a against COVID-19 from the DisCoVeRy randomized controlled trial. 1 The DisCoVeRy trial is a French-led add-on trial to the WHO Solidarity trial. Hospitalized patients could be included at any time after symptom onset, provided they were not previously treated with any of the study medications and that a PCR test was positive for SARS-COV-2 within 72 hours of enrolment. The trial targeted the recruitment of 620 patients in each treatment arm but was stopped for futility after the inclusion of about 145 patients per arm, before reaching the formal futility stopping criteria defined in the trial's protocol. Patients were included at a median of 9 days after symptom onset, about 60% required low-flow supplemental oxygen and more than 40% were in the ICU when recruited. There was no advantage to all treatment arms -hydroxychloroquine for 10 days; lopinavir/ritonavir for 14 days; or lopinavir/ritonavir with 3 doses of subcutaneous interferon-β-1a -compared with standard of care. A trend for worst outcomes, that reached statistical significance in few outcomes, was seen among patients randomized to lopinavir/ritonavir and interferon-β-1a. Serious adverse events were significantly more frequent in both lopinavir/ritonavir arms. Confidence intervals of the treatment effects were broad, and the trial was not powered to prove equivalence between standard of care and the different treatments. However, results are similar to the ones observed in the Solidarity trial, recruiting 954, 1411 and 651 patients to three arms -hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir with interferon-β-1a, respectively; 2 results of the RECOVERY study including 1616 patients randomized to lopinavir/ritonavir 3 ; and results of 12 RCTs involving 8,569 participants randomized to hydroxychloroquine. 4, 5 J o u r n a l P r e -p r o o f

The efforts invested in examining treatments with no effects raises the question of the threshold required to launch a RCT of a repurposed drug. Was there a justifiable scientific rationale to launch large RCTs assessing all the repurposed drugs that were assessed for COVID-19? Was there a need to randomize more than 4000 patients to lopinavir/ritonavir and more than 8000 to hydroxychloroquine? Wasted efforts were invested in many more trials with the same drugs that were planned, designed, even launched, but discontinued. 6 Conversely, the situation where individual physicians, most not specialized in infectious diseases, started using medications based on opinions, limited experience, social media, non-peer-reviewed publications and poorly-conducted observational studies is unacceptable, because it provides false hopes and may harm patients. 7 Off-label use of repurposed drugs, provided probably to many millions globally, further inflated biased data on these medications, leading to poorly designed observational studies conducted by investigators with strong personal or commercial biases, many with the good and sincere intention of finding cure for this severe new disease. Clearly, RCTs are the only appropriate design to examine the effects of repurposed drugs and these should be launched as soon as possible during a pandemic such as COVID-19. Thus, there is a fine line between futility and need for RCTs assessing repurposed drugs for COVID-19 or other pandemics.

We believe that there is a need for a structured pre-clinical pathway for repurposed drugs that will serve as a threshold for testing the most promising drugs in randomized controlled trials (RCTs). Subsequently, the entry of the drug for clinical use for a new indication must . The COVID-19 experience has taught us that despite having been approved for another indication, pharmacokinetics and safety should be monitored for the repurposing indication, because unexpected harm may occur for the same drug that has been safe J o u r n a l P r e -p r o o f before, but not anymore for a different disease, specifically, an infection. 6, 7 In the Discovery trial, higher than expected drug levels of lopinavir were observed, possibly underlying the higher rate of adverse event events, specifically kidney injury, in the lopinavir-containing arms compared to the control arm. 1 Gastrointestinal adverse events were more common with lopinavir-ritonavir compared to standard of care in another small RCT. 9 Drug levels were not measured in the SOLIDARITY and RECOVERY trials and monitoring of adverse events in these trials was sparse.

Finally, a word on medical journal editors' responsibility during the COVID-19 pandemic and in future such events. Being the first to publish on a disease and on its treatment is attractive to journals, but this should be left to standard journalism. Medical journals should be attracted to evidence-based medicine. Even in pandemics and especially in pandemics, the rigor of evaluating the quality of studies published needs to be maintained. Publication of poorly conducted studies claiming effects in peer-reviewed journals has many negative consequences: misdirects patients' treatment, leads to wasted research efforts, affects trust in science, and delays the public health implementation of needed scientific measures to end the pandemic. During this pandemic we hope to have learned more on the positive and negative impact of medical journals, as well as on the importance of effective clinical research and evidence-based medicine for the optimal management of this ongoing and future emerging events.

An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

Review of trials currently testing treatment and prevention of COVID-19

Treating COVID-19-Off-Label Drug Use, Compassionate Use, and

Stepping in the Same River Twice